title: Prevention of postmenopausal bone loss and endometrial responses during a two year prospective study with transdermal 17 beta-estradiol and oral medroxyprogesterone acetate.
authors.affiliation: Department of Obstetrics and Gynecology, University of Pisa, School of Medicine, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Fioretti
authors.forename: M
authors.initials: M
authors.lastname: Gambacciani
authors.forename: A
authors.initials: A
authors.lastname: Spinetti
authors.forename: A
authors.initials: A
authors.lastname: Cagnacci
authors.forename: A M
authors.initials: AM
authors.lastname: Paoletti
authors.forename: R
authors.initials: R
authors.lastname: Felipetto
authors.forename: G B
authors.initials: GB
authors.lastname: Melis
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004717:Endometrium / Q000187:drug effects* / Q000502:physiology; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone